Filing Details

Accession Number:
0001209191-16-136460
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-10 19:28:38
Reporting Period:
2016-08-08
Filing Date:
2016-08-10
Accepted Time:
2016-08-10 19:28:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
805928 Axogen Inc. AXGN Electromedical & Electrotherapeutic Apparatus (3845) 411301878
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1375003 M Joseph Mandato 14612 Big Basin Way
Saratoga CA 95070
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-08-08 107,450 $8.63 1,268,941 No 4 S Indirect By De Novo Ventures II, L.P.
Common Stock Disposition 2016-08-09 42,168 $8.30 1,226,773 No 4 S Indirect By De Novo Ventures II, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By De Novo Ventures II, L.P.
No 4 S Indirect By De Novo Ventures II, L.P.
Footnotes
  1. Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $8.50 and $8.67 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  2. The Form 4 filed with the SEC on June 3, 2015 over reported the amount of securities beneficially owned following the reported transaction by one share, which has been corrected in this filing.
  3. The shares are owned by De Novo Ventures II, L.P. ("DNV II"). De Novo Management II, LLC is the sole general partner of DNV II. The reporting person is a managing member of De Novo Management II, LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $8.27 and $8.34 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.